Business
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD -\nPALO ALTO, Calif., Sept. 25, 2025 /PRNewswire/ -- Respira Therapeutics, Inc. (Respira or the \"Company\"), a Samsara BioCapital portfolio company, today announced that it has entered into an agreement with Gossamer Bio, Inc. (Gossamer) (Nasdaq: GOSS) granting Gossamer an option to acquire the Company. \n\n \n \n \n \n \n \n\n \nRespira is developing RT234 (vardenafil inhalation powder) as the first as-needed (PRN) therapy for use in pulmonary hypertension (PH). RT234 is designed to rapidly improve PH patient function and symptoms, including for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). There are no approved PRN therapies for PAH or PH-ILD, and despite existing treatment options, the majority of PH patients continue to struggle with debilitating symptoms that disrupt daily life and limit their independence.\n\"We look forward to working closely with our colleagues at Gossamer, who share our commitment to people living with PH, to expeditiously develop RT234 and making this unique therapy broadly available to patients,\" stated John Kollins, Respira's Chief Executive Officer.\n\"We are excited to pair Respira's technology and expertise with Gossamer's established late-stage PH product development platform,\" said Michael Dybbs, member of the Respira Board of Directors and partner at Samsara BioCapital. \"We are confident that this transaction favorably positions RT234 to advance into late-stage clinical development.\" \nPursuant to the option agreement, Gossamer is issuing 2.5 million shares of common stock in connection with the signing. Additionally, upon exercise of its acquisition option, Gossamer will issue an additional 1.5 million shares of common stock. In addition, the acquisition agreement provides for certain success-based clinical, regulatory, and commercial milestone payments and a royalty on potential net sales of RT234. During the option period, which is anticipated to continue for up to approximately two years, Gossamer will fund and Respira will undertake certain pre‑agreed development activities focused on CMC work necessary to position RT234 for successful subsequent c...